title: [Bone densitometry in inflammatory rheumatic diseases : Characteristics of the measurement site and disease-specific factors].
abstract: Bone densitometry should be performed earlier in patients with inflammatory arthritis, since factors such as inflammation and drug therapy, in particular treatment with glucocorticoids, have an important impact on the development of osteoporosis. DXA (Dual energy X-ray Absorptiometry) is considered the gold standard for bone densitometry. According to the German guidelines for osteoporosis, bone densitometry plays a crucial role in the choice of therapy.In patients with rheumatoid arthritis, measurement of peripheral bone (forearm) density in addition to lumbar spine and hip is recommended, since local bone loss is pathognomonic for this disease. DXA measurements of the hand enable the diagnosis of juxtaarticular osteoporosis at an earlier stage; however, this has not yet been established in routine practise.Bone measurement in patients with ankylosing spondylitis can be performed in the lumbar spine and the hip at disease onset. In systemic lupus erythematosus, bone loss is more frequent in patients with high inflammatory activity. Patients with psoriasis arthritis frequently have osteoporosis in the case of a destructive development of the joints.
authors.affiliation: Schwerpunktpraxis Rheumatologie, Godesberger Allee 90, 53175, Bonn, Deutschland. Hgfranck@gmx.de
authors.forename: H
authors.initials: H
authors.lastname: Franck
authors.forename: J
authors.initials: J
authors.lastname: Braun
authors.forename: F
authors.initials: F
authors.lastname: Buttgereit
authors.forename: W
authors.initials: W
authors.lastname: Demary
authors.forename: G
authors.initials: G
authors.lastname: Hein
authors.forename: J
authors.initials: J
authors.lastname: Kekow
authors.forename: G
authors.initials: G
authors.lastname: Schett
authors.forename: P M
authors.initials: PM
authors.lastname: Kern
mesh_terms: D015502:Absorptiometry, Photon; D015535:Arthritis, Psoriatic / Q000175:diagnosis; D001172:Arthritis, Rheumatoid / Q000175:diagnosis* / Q000188:drug therapy; D002097:C-Reactive Protein / Q000378:metabolism; D005260:Female; D005598:Fractures, Spontaneous / Q000517:prevention & control; D005938:Glucocorticoids / Q000009:adverse effects / Q000627:therapeutic use; D018737:Hand Strength; D006801:Humans; D008180:Lupus Erythematosus, Systemic / Q000175:diagnosis / Q000188:drug therapy; D008297:Male; D010024:Osteoporosis / Q000139:chemically induced / Q000175:diagnosis* / Q000188:drug therapy; D017410:Practice Guidelines as Topic; D012216:Rheumatic Diseases / Q000175:diagnosis* / Q000188:drug therapy; D012307:Risk Factors; D013167:Spondylitis, Ankylosing / Q000175:diagnosis / Q000188:drug therapy
chemical_list: D005938:Glucocorticoids; D002097:C-Reactive Protein